Physician profile
David Immanuel
NPI 1053352658
$8,981.13
in general payments reported to CMS, 2019-2025
34 companies · $3,428 in 2025
The $3,428 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $323 · 2021: $635 · 2022: $973 · 2023: $901 · 2024: $1,719 · 2025: $3,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.90 |
| Travel and Lodging | $967.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,133.41 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,099.82 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Alcon Vision LLC | $851.23 | 2021-2025 | Tryptyr, Clareon, Simbrinza |
| Abbvie INC. | $751.66 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $616.32 | 2019-2025 | Cequa |
| Rxsight INC | $546.22 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $471.47 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $375.79 | 2019-2021 | |
| Glaukos Corporation | $276.12 | 2019-2023 | Gts100-Glaukos Istent Trabecular Micro-Bypass Stent System, Istent Trabecular Micro-Bypass Stent System |
| Johnson & Johnson Surgical Vision, INC. | $275.08 | 2024-2025 | Tecnis Simplicity, Amo Phaco Needle |
| Aerie Pharmaceuticals, INC. | $274.09 | 2019-2021 | |
| Harrow Eye, LLC | $244.49 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $200.55 | 2022-2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $198.24 | 2021-2025 | Acthar |
| Amgen INC. | $197.70 | 2025 | Tepezza |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Immanuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.